Zacks Research Has Optimistic Outlook of Humana Q1 Earnings

Humana Inc. (NYSE:HUM - Free Report) - Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Humana in a report issued on Tuesday, February 25th. Zacks Research analyst D. Chatterjee now forecasts that the insurance provider will post earnings per share of $9.91 for the quarter, up from their prior estimate of $6.37. The consensus estimate for Humana's current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana's Q2 2025 earnings at $5.31 EPS, Q3 2025 earnings at $2.87 EPS, Q4 2025 earnings at ($1.85) EPS, Q2 2026 earnings at $4.29 EPS, Q4 2026 earnings at ($2.41) EPS and FY2026 earnings at $10.92 EPS.

Several other brokerages have also recently weighed in on HUM. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research note on Tuesday, February 18th. Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. StockNews.com upgraded shares of Humana from a "hold" rating to a "buy" rating in a research note on Tuesday, February 25th. Barclays lifted their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. Finally, Bank of America upgraded shares of Humana from an "underperform" rating to a "neutral" rating and lifted their price objective for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Nineteen investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Humana presently has an average rating of "Hold" and a consensus target price of $285.68.

Humana Stock Performance

Shares of NYSE HUM traded down $8.44 during mid-day trading on Friday, reaching $261.98. 448,577 shares of the company were exchanged, compared to its average volume of 1,677,575. The company's 50-day simple moving average is $271.11 and its 200-day simple moving average is $286.36. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $31.61 billion, a P/E ratio of 26.35, a P/E/G ratio of 2.05 and a beta of 0.56. Humana has a twelve month low of $213.31 and a twelve month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%.

Institutional Investors Weigh In On Humana

Institutional investors have recently added to or reduced their stakes in the business. Creative Financial Designs Inc. ADV grew its holdings in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock worth $27,000 after acquiring an additional 61 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Humana during the 3rd quarter worth approximately $31,000. FPC Investment Advisory Inc. acquired a new position in shares of Humana in the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana in the 4th quarter worth approximately $30,000. Finally, LFA Lugano Financial Advisors SA lifted its position in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares during the period. 92.38% of the stock is owned by institutional investors.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company's stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.32% of the stock is currently owned by insiders.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.35%. The ex-dividend date of this dividend is Friday, March 28th. Humana's dividend payout ratio (DPR) is presently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.